Novartis : Sandoz to be listed on around 4 October
>Beneficial effects of the spin-off for Novartis - With the aim of refocusing on its core business of innovative medicine, Novartis is planning to spin-off its subsidiary Sandoz (generics activity) on around 4 October 2023. As a reminder, this activity represented 18% of the group's sales and 11% of its core EBIT in 2022. We think that such an operation will have immediate beneficial effects: a more readable group, easier to manage and focused on higher-margin activit...Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.